for Health Care Providers
|LABORATORY VALUES||MANUFACTURER PACKAGE INSERT RECOMMENDATIONS|
ANC = absolute neutrophil count; WBC = white blood cell counts
*If dose is maintained outside of manufacturer recommendations, monitor ANC more frequently and counsel patient on neutropenic precautions. In cirrhotic, post-liver transplantation or HIV/HCV coinfected patients who remain neutropenic despite dose reduction, consider starting GCSF until resolution.
If dose is maintained outside of manufacturer recommendations, monitor platelet counts more frequently and for signs and symptoms of unusual bleeding or bruising.
|<1.5 x 109/L||Reduce peginterferon alfa-2b dose by 50% and reevaluate|
|<1.0 x 109/L||Discontinue peginterferon alfa-2b until resolution|
|<0.75 x 109/L||Peginterferon alfa-2a: reduce dose to 135 mcg/wk and reevaluate|
Peginterferon alfa-2b: reduce dose by 50% and reevaluate
|<0.50 x 109/L||Discontinue peginterferon alfa until resolution|
|<80 k/mm3||Peginterferon alfa-2b: reduce dose by 50% and reevaluate|
|<50 k/mm3||Peginterferon alfa-2a: reduce dose to 90 mcg/wk and reevaluate|
Peginterferon alfa-2b: discontinue until resolution
|<25 k/mm3||Peginterferon alfa-2a: discontinue until resolution|